PMS-EVEROLIMUS 5 MG — DIN 02504685
EVEROLIMUS : 5 MG · PHARMASCIENCE INC · TABLET · wholesale supply in Canada
Health Canada status: MARKETED
What is PMS-EVEROLIMUS?
PMS-EVEROLIMUS 5 MG contains EVEROLIMUS : 5 MG. It is listed in the Health Canada Drug Product Database under DIN 02504685, held by PHARMASCIENCE INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 08-Sep-2021. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is PMS-EVEROLIMUS used for?
pms-EVEROLIMUS (everolimus) is indicated for: the treatment of postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer in combination with exemestane after recurrence or progression following treatment with letrozole or anastrozole. The effectiveness of everolimus in advanced breast cancer is based on a demonstration of progression-free survival (PFS) benefit. Clinical benefit such as prolongation of overall survival (OS) or improvement in quality-of-life (QOL) has not been demonstrated. The treatment of well- or moderately differentiated neuroendocrine tumours of pancreatic origin (PNET) in patients with unresectable, locally advanced or metastatic disease that has progressed within the last 12 months. The effectiveness of everolimus in PNET is based on demonstrated progression-free survival (PFS) benefit in a phase III placebo-controlled study in patients with documented progressive disease within 12 months of randomization. There was no evidence of an overall survival (OS) benefit and quality of life (QOL) was not measured. The treatment of unresectable, locally advanced or metastatic, well-differentiated, non-functional neuroendocrine tumours (NET) of gastrointestinal or lung origin in adults with progressive disease. The effectiveness of everolimus in gastrointestinal or lung NET is based on demonstrated progression-free survival (PFS) benefit in a phase III placebo-controlled study in patients whose disease had progressed within 6 months of randomization. An overall survival (OS) benefit or improvement in quality of life (QOL) has not been demonstrated. Subgroup analyses suggested that patients with better prognosis benefited less from pms-EVEROLIMUS treatment. pms-EVEROLIMUS in combination with a somatostatin analogue is not indicated for the treatment of patients with neuroendocrine tumours from gastrointestinal or lung origin. pms-EVEROLIMUS is not indicated for the treatment of patients with functional carcinoid tumours. The treatment of patients with metastatic renal cell carcinoma (RCC) of clear cell morphology, after failure of initial treatment with either of the vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGF-receptor TKIs) sunitinib or sorafenib. The effectiveness of everolimus is based on PFS. Prolongation of OS was not demonstrated for everolimus in RCC nor were quality-of-life differences shown between patients receiving everolimus versus placebo in the pivotal phase III trial. The treatment of adult patients (≥ 18 years of age) with renal angiomyolipoma associated with tuberous sclerosis complex (TSC), who do not require immediate surgery. The effectiveness of everolimus in the treatment of renal angiomyolipoma is based on an analysis of objective responses in patients treated for a median of 8.3 months in the pivotal phase III placebo-controlled trial. pms-EVEROLIMUS is indicated for: the treatment of patients with subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC) that have demonstrated serial growth, who are not candidates for surgical resection and for whom immediate surgical intervention is not required. The effectiveness of everolimus is based on an analysis of change in SEGA volume. Prescribers should take into consideration that surgical resection can be curative, while treatment with everolimus has been shown only to reduce the SEGA volume.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Everolimus cost around the world?
Everolimus is listed on 16 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Bahrain publishes a retail (max); Greece publishes a producer price (ex-factory). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| South Africa | single exit price | 198 | 203 | ZAR███.██ |
| United States | acquisition | 6 | 57 | USD███.██ |
| Australia | ex-manufacturer | 3 | 48 | AUD███.██ |
| Sweden | AIP (pharmacy purchase price) | 9 | 28 | SEK███.██ |
| Greece | producer price (ex-factory) | 20 | 20 | EUR███.██ |
| Norway | max AUP (pharmacy retail) | 3 | 20 | NOK███.██ |
| Hungary | producer price (ex-factory) | 15 | 17 | HUF███.██ |
| Romania | max producer price | 13 | 17 | RON███.██ |
| Saudi Arabia | public | 9 | 14 | SAR███.██ |
| Slovakia | categorised final price | 14 | 14 | EUR███.██ |
| Bahrain | retail (max) | 3 | 9 | BHD███.██ |
| Italy | ex-factory (classe H) | 4 | 8 | EUR███.██ |
| Spain | PVP con IVA (public price) | 6 | 6 | EUR███.██ |
| United Arab Emirates | public | 5 | 5 | AED███.██ |
| Italy | prezzo al pubblico (classe A) | 5 | 5 | EUR███.██ |
| United Kingdom | hospital | 3 | 3 | GBP███.██ |
| Iceland | max wholesale | 1 | 1 | ISK███.██ |
475 pack listings across 317 brand entries and 15 price bases, refreshed 08 Sep 2026. Ranges span every Everolimus pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Everolimus in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
6 holders have a Canadian DIN containing Everolimus, across 28 DINs, of which 21 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| NOVARTIS PHARMACEUTICALS CANADA INC | 10 | 6 | AFINITOR, AFINITOR DISPERZ, CERTICAN | Sourceable in Canada |
| DR REDDY'S LABORATORIES LTD | 4 | 3 | REDDY-EVEROLIMUS | Sourceable in Canada |
| NATCO PHARMA (CANADA) INC | 4 | 3 | NAT-EVEROLIMUS | Sourceable in Canada |
| TEVA CANADA LIMITED | 4 | 3 | TEVA-EVEROLIMUS | Sourceable in Canada |
| PHARMASCIENCE INC | 3 | 3 | PMS-EVEROLIMUS | Sourceable in Canada |
| SANDOZ CANADA INCORPORATED | 3 | 3 | SANDOZ EVEROLIMUS | Sourceable in Canada |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 5 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
| Pack configuration (monograph) | null |
| Storage | null |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Everolimus |
|---|---|
| ATC code | L04AH02 |
| AHFS class | 10:00.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02504685 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2504685 |
| Brand name | PMS-EVEROLIMUS |
| Generic / active ingredient | EVEROLIMUS : 5 MG |
| Market authorization holder | PHARMASCIENCE INC |
| Health Canada schedule | Prescription |
| ATC code | L04AH02 |
| ATC anatomical main group | L — Antineoplastic and immunomodulating agents |
| ATC therapeutic subgroup | L04AH |
| Current status | MARKETED |
| Status date | 08-Sep-2021 |
| Original market date | 2021-09-08 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
21 of 28 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| AFINITOR | 2.5 MG | TABLET | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED | 02369257 |
| AFINITOR | 5 MG | TABLET | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED | 02339501 |
| AFINITOR | 10 MG | TABLET | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED | 02339528 |
| AFINITOR DISPERZ | 2 MG | TABLET FOR SUSPENSION | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED | 02425645 |
| AFINITOR DISPERZ | 3 MG | TABLET FOR SUSPENSION | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED | 02425653 |
| AFINITOR DISPERZ | 5 MG | TABLET FOR SUSPENSION | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED | 02425661 |
| NAT-EVEROLIMUS | 2.5 MG | TABLET | NATCO PHARMA (CANADA) INC | MARKETED | 02530090 |
| NAT-EVEROLIMUS | 5 MG | TABLET | NATCO PHARMA (CANADA) INC | MARKETED | 02530104 |
| NAT-EVEROLIMUS | 10 MG | TABLET | NATCO PHARMA (CANADA) INC | MARKETED | 02530120 |
| PMS-EVEROLIMUS | 2.5 MG | TABLET | PHARMASCIENCE INC | MARKETED | 02504677 |
2 · Same class — other molecules in ATC L04AH
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Everolimus | AFINITOR · AFINITOR DISPERZ · CERTICAN · NAT-EVEROLIMUS · +4 more | 28 | 21 | Yes |
| Sirolimus | GD-SIROLIMUS · RAPAMUNE | 8 | 2 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC L04A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| L04AX | Azathioprine · Dimethyl Fumarate · Lenalidomide · Methotrexate · Other Immunosuppressants · +3 more | 191 | 124 |
| L04AC | Anakinra · Basiliximab · Bimekizumab · Brodalumab · Canakinumab · +13 more | 85 | 75 |
| L04AB | Adalimumab · Certolizumab Pegol · Etanercept · Golimumab · Infliximab | 71 | 55 |
| L04AA | Abatacept · Alefacept · Antilymphocyte Immunoglobulin (Horse) · Antithymocyte Immunoglobulin (Rabbit) · Apremilast · +4 more | 73 | 42 |
| L04AD | Ciclosporin · Tacrolimus | 49 | 30 |
| L04AK | Leflunomide · Teriflunomide | 44 | 25 |
| L04AF | Baricitinib · Deucravacitinib · Ritlecitinib · Tofacitinib · Upadacitinib | 23 | 19 |
| L04AG | Alemtuzumab · Anifrolumab · Belimumab · Efalizumab · Inebilizumab · +7 more | 20 | 15 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is PMS-EVEROLIMUS called?
The same molecule, Everolimus, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Afinitor | Latin | Australia, Bahrain, Norway |
| Certican | Latin | Australia, Bahrain, Norway, South Africa |
| Everocan | Latin | Australia |
| Votubia | Latin | Norway, Romania |
| Afinitor® | Latin | Sweden |
| Avrolem | Latin | Bahrain, Saudi Arabia |
| Evatoc | Latin | Saudi Arabia |
| Everolimus Avansor | Latin | Sweden |
| Everolimus Krka | Latin | Sweden |
| Everolimus Sandoz | Latin | Sweden |
| Everolimus STADA | Latin | Sweden |
| Everolimus Teva | Latin | Sweden |
| Everolimus Zentiva | Latin | Sweden |
| Votubia® | Latin | Sweden |
| Everolimus BOS | Latin | Saudi Arabia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.